










Biennial meeting	s with ESID and INGID
Rhodes Greece	1998
Geneva Switzerland	2000
Weimar Germany	2002
Versailles France	2004
Budapest Hungary	2006
Den Bosch Netherland	ds 2008
Istanbul Turkey	2010
The global organisation working to improve the quality of life	for people with primary immunodeficiencies





Last update : Dicembre 2007	Haster	Haster	Hastor	ABiotest	CSL Behring	CSL Behring	K	GRIFOLS
Company	Baster	Baster	Rester	Dictest Pharma GmbH	CSL-Behring	CSL-Behring	Kednion	Grifole
Name of product	Gammagard S/D	Endobulin S/D	SUBCUMA	Intraglobin® F	Sandoglobulin (7yo)	Vivaglobin	IG VENA	Flebogamma
Available for Hospital therapy	Yes	Yes	Yes	Yes	Registered	Registered	Yes	Yes
Available for Home therapy	May vary in different countries due to different licensing situations.	May vary in different countries due to different licensing situations.	Yes	not available for home therapy		Yes	None	
IVIG, SCIG or IMIG	M3	1/03	8013	1013	NNG	5010	1/03	103
Patient's age	All ages	Al ages	Adults and juveniles at the age of 2 12 years	unlimited	Adults and children	Adults and children	Adulta & Children	
Présectation	Lyophilised Powder	Lysphilised Powder	Liquid	ready-to-use solution	Lyophilisat	Liquid	Liquid	Liquid
Concentration %	5% or 10%	5%	1956	5% solution	3%, 6%, 9%, 12%	16%	5%	5%
Content of IgG	2.90%	95% immunoglabilin	3 90%	> 66%	2 99%	IgG monomers & dimers 97-97% • IgG polymers 3-5%	90%	2 99%
lgG1	63%	50-82%	45-75%	82%	00.7%	61%	24,3 - 37,2 mg	70.3%
lgG2	21,02%	20-52%	20-45%	34%	31.8%	28%	12,4 - 22,1 mg	24.7%
1203	5,40%	< 0.5%	3-10%	0.5%	3.8%	5%	0,0 - 1,5 mg	3.1%
IgG4 Content of IgA	0.20% \$3 up/ml	1-3% \$ 0.05 moltri	2-8% \$4.8 mg/ml	3.5% \$ 2.5 maini	3.0% 1.231 (typical value)	6% max 17 ol	0.1 - 0.5 mg	2%
Content of IgA	2 3 blours	s allo mons	3 4.8 mg/m	s 2.5 mgm	1.291 (typical value)	max 1/9L	< 0,05 mgmil	<0,05 mg/ml
Clucose, Maltose,	Glucose	ENDOBULIN S/D contains 1 gram of glucose per gram of immunoglobulin G.	Glycine	glucose 25 mg	Sucrose	Glycine	Malicso	
Average dosage for PID	The dose and dosege	dosage regimen may need to be individualised depending on pharmacokinetic and clinical response	circulating IgG. • The dose and dosage regimen may need to		0.2-0.8g/kg bodyweight	0.2-0.8gkg bodyweght	0,4 - 0,8 g/kg	







